Revenue Outlook Disappoints: Recent discussions on social media about CorMedix Inc. have centered on the company’s 2026 revenue guidance. Many users expressed concern over the projected revenue of $300 million to $320 million, which falls short of earlier expectations. The stock saw a sharp decline in early trading following this news.
Leadership Updates: Alongside financial updates, chatter has also focused on recent leadership changes at CorMedix. The extension of the CEO’s contract and new board appointments have sparked mixed reactions. Some see this as a stabilizing move, while others remain skeptical amid the revenue concerns.
Note: This discussion summary was generated from an AI condensation of post data.
CorMedix Inc. Insider Trading Activity
CorMedix Inc. insiders have traded $CRMD stock on the open market 14 times in the past 6 months. Of those trades, 1 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $CRMD stock by insiders over the last 6 months:
- JANET DILLIONE has made 0 purchases and 4 sales selling 137,000 shares for an estimated $1,478,755.
- JOSEPH TODISCO (Chief Executive Officer) has made 0 purchases and 2 sales selling 80,000 shares for an estimated $1,010,000.
- ELIZABETH HURLBURT (Chief Operating Officer) has made 0 purchases and 2 sales selling 53,997 shares for an estimated $711,817.
- KAUFMAN BETH ZELNICK (Chief Legal Officer) has made 0 purchases and 2 sales selling 50,000 shares for an estimated $670,264.
- STEVEN W LEFKOWITZ sold 40,000 shares for an estimated $475,200
- ALAN W DUNTON has made 0 purchases and 2 sales selling 30,000 shares for an estimated $391,300.
- MYRON KAPLAN purchased 25,000 shares for an estimated $275,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CorMedix Inc. Revenue
CorMedix Inc. had revenues of $104.3M in Q3 2025. This is an increase of 810.22% from the same period in the prior year.
You can track CRMD financials on Quiver Quantitative's CRMD stock page.
CorMedix Inc. Hedge Fund Activity
We have seen 142 institutional investors add shares of CorMedix Inc. stock to their portfolio, and 60 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. added 3,323,833 shares (+inf%) to their portfolio in Q3 2025, for an estimated $38,656,177
- MARSHALL WACE, LLP added 893,518 shares (+34.6%) to their portfolio in Q3 2025, for an estimated $10,391,614
- UBS GROUP AG added 814,964 shares (+295.3%) to their portfolio in Q3 2025, for an estimated $9,478,031
- JUMP FINANCIAL, LLC added 774,083 shares (+inf%) to their portfolio in Q3 2025, for an estimated $9,002,585
- NUVEEN, LLC removed 772,997 shares (-52.6%) from their portfolio in Q3 2025, for an estimated $8,989,955
- GHISALLO CAPITAL MANAGEMENT LLC removed 750,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,722,500
- ANSON FUNDS MANAGEMENT LP removed 725,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,431,750
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CorMedix Inc. Analyst Ratings
Wall Street analysts have issued reports on $CRMD in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 12/18/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/13/2025
- Needham issued a "Buy" rating on 11/12/2025
- RBC Capital issued a "Outperform" rating on 10/21/2025
- JMP Securities issued a "Market Outperform" rating on 09/09/2025
To track analyst ratings and price targets for CorMedix Inc., check out Quiver Quantitative's $CRMD forecast page.
CorMedix Inc. Price Targets
Multiple analysts have issued price targets for $CRMD recently. We have seen 5 analysts offer price targets for $CRMD in the last 6 months, with a median target of $18.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $14.0 on 12/18/2025
- Brandon Folkes from HC Wainwright & Co. set a target price of $18.0 on 11/13/2025
- Serge Belanger from Needham set a target price of $16.0 on 11/12/2025
- Leonid Timashev from RBC Capital set a target price of $22.0 on 10/21/2025
- Jason N. Butler from JMP Securities set a target price of $22.0 on 09/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
